Type 4 P-type ATPases (P4-ATPases) are lipid flippases that drive the active transport of phospholipids from exoplasmic or luminal leaflets to cytosolic leaflets of eukaryotic membranes. The molecular architecture of P4-ATPases and the mechanism through which they recognize and transport lipids have remained unknown. Here we describe the cryoelectron microscopy structure of the P4-ATPase Drs2p-Cdc50p, a Saccharomyces cerevisiae lipid flippase that is specific to phosphatidylserine and phosphatidylethanolamine. Drs2p-Cdc50p is autoinhibited by the C-terminal tail of Drs2p, and activated by the lipid phosphatidylinositol-4-phosphate (PtdIns4P or PI4P). We present three structures that represent the complex in an autoinhibited, an intermediate and a fully activated state. The analysis highlights specific features of P4-ATPases and reveals sites of autoinhibition and PI4P-dependent activation. We also observe a putative lipid translocation pathway in this flippase that involves a conserved PISL motif in transmembrane segment 4 and polar residues of transmembrane segments 2 and 5, in particular Lys1018, in the centre of the lipid bilayer.
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. Owing to membrane-fusion events and the bidirectional and gradient-dissipating activity of lipid scramblases, lipid asymmetry must constantly be regulated and restored. Members of two distinct superfamilies of membrane proteins drive the ATPdependent unidirectional translocation of lipids against concentration gradients. ATP-binding cassette (ABC) transporters typically drive the inward-to-outward (flop) translocation of lipids between bilayer leaflets, whereas P4-ATPases drive the outward-to-inward (flip) process [1] [2] [3] [4] . The P-type ATPases couple transport to the formation and breakdown of the phosphoenzyme through a functional cycle that involves several intermediate states (E1, E1P, E2P and E2) (Extended Data Fig. 1a ). P4-ATPases couple lipid transport to dephosphorylation of the E2P state 5, 6 , in a manner that is similar to the inward transport of potassium by the Na + , K + -ATPase. Conversely, phosphorylation of E1P appears to be independent of transport 5,7 (Extended Data Fig. 1a, b ). Although previous work has shed light on the structure and mechanism of lipid floppases 8,9 and scramblases 10, 11 , P4-ATPases have so far been studied only through bioinformatics and functional assays. Models have identified potential peripheral or centrally located lipid-recognition sites and pathways [12] [13] [14] , but the mechanism of transport remains a source of debate.
Most P4-ATPases are binary complexes that contain a subunit from the CDC50 family of proteins; this subunit is necessary for the correct localization and function of the complex 15, 16 (Extended Data Fig. 1c ). Mutant forms of mammalian lipid flippases have been implicated in various diseases; for example, ATP8A1 and ATP8A2 in neurological disorders, ATP8B1 in progressive familial intrahepatic cholestasis type 1, ATP10A in type 2 diabetes and insulin resistance and ATP11A in cancer 17 . The trans-Golgi-localized Drs2p-Cdc50p complex from the yeast S. cerevisiae is well-characterized. In vivo 18, 19 and in vitro 20, 21 studies have shown that Drs2p-Cdc50p primarily flips phosphatidylserine (and-to a lesser extent-phosphatidylethanolamine) from the luminal side to the cytosolic leaflet, and indicate that this function may have a role in the biogenesis of vesicles at late secretory membranes 22 . The C terminus of Drs2p contains an autoinhibitory domain 23, 24 , and relief of autoinhibition requires the regulatory lipid PI4P 6, 23 . Binding of Gea2p (a guanine nucleotide exchange factor for the small GTPase Arf) to a basic segment of the C terminus has previously been reported to be necessary for activation of Drs2p in vivo 23 , although this finding has not yet been confirmed in vitro 24 . Furthermore, interaction of Arl1p (a GTPase of the Arf family) with the extended N terminus of Drs2p has been implicated in flippase activity in vivo 25 . The first 104 amino acids of the N terminus have little effect on in vitro activity; by contrast, truncation of the C terminus is activating, but the protein continues to be under regulation by PI4P 26 (Extended Data Fig. 1d ). Although these studies highlight the components that are involved, a molecular mechanism of autoregulation for Drs2p-Cdc50p (and P-type ATPases in general) remains unknown.
To gain structural and mechanistic insights, we embarked on cryo-electron microscopy (cryo-EM) studies of Drs2p-Cdc50p complexes, stabilized with beryllium fluoride (BeF 3 − ). Drs2p-Cdc50p was overexpressed in S. cerevisiae and purified in lauryl maltose neopentyl glycol (LMNG) detergent by affinity chromatography and gel filtration, resulting in a monodisperse sample that contained both subunits of the complex (Extended Data Fig. 2 ). The resulting structures are in conformations that are consistent with an E2P phosphoenzyme and capture the progressive steps from a fully autoinhibited P4-ATPase (E2P 
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Overall structure and conformation
The structures of Drs2p-Cdc50p in the E2P inhib , E2P
inter and E2P active conformations were determined at resolutions of 2.8, 3.7 and 2.9 Å, respectively, and reveal functional sites and the PI4P-dependent regulation of Drs2p-Cdc50p (Extended Data Table 1 ). Complete models, except for minor disordered regions at the termini, were obtained (Supplementary Video 1). The structure of the Drs2p subunit is typical of P-type ATPases (see Supplementary Discussion) with ten transmembrane helices and three cytosolic domains: the actuator (A) domain, the nucleotide-binding (N) domain and the phosphorylation (P) domain (Fig. 1, Extended  Data Fig. 1c, e-g ). The Cdc50p subunit has an ectodomain with two asymmetric lobes. The first is dominated by an antiparallel β-sandwich, and the other contains little secondary structure apart from short helical segments (Extended Data Fig. 3a) . Two previously identified 27 disulfide bonds are evident (Extended Data Fig. 3b ), and at least one N-acetylglucosamine unit of each of the four glycosylation sites is revealed by the map (Extended Data Fig. 3c-e) . The fold of the ectodomain is similar to the lipid-binding protein seipin, although some loops of Cdc50p are considerably longer than those of seipin (Extended Data Fig. 3f ). The two transmembrane helices of Cdc50p extend from the N terminus and the C terminus of the first lobe of the ectodomain (Extended Data Fig. 3a ) and interact closely with each other and with transmembrane helix 10 (TM10) of Drs2p (Extended Data Fig. 3g ).
Extensive quaternary interactions appear on the luminal face, in which conserved regions of the Cdc50p ectodomain interact with all of the luminal loops of Drs2p (Fig. 1b, Extended Data Fig. 3h-k) . The TM3-TM4 loop stretches into a conserved interaction site at the ectodomain of Cdc50p (Extended Data Fig. 3h) , and the N terminus of Cdc50p extends along the cytosolic side of the transmembrane domain of Drs2p and makes contacts with a segment (residues 529-538) that connects TM4 and the phosphorylation site of the P domain (Extended Data Fig. 3a, i) . This segment is conserved in length in P-type ATPases and couples the chemistry of the phosphorylation site with conformational changes of the transmembrane domain 28 , and in P4-ATPases, specifically, the segment is ten residues longer. For a detailed description of Drs2p-Cdc50p interactions, see Supplementary Information.
Autoinhibition and PI4P binding
Our samples reveal three distinct states that lead from autoinhibition to activation. In E2P inhib , the autoinhibitory C terminus forms an extensive interface (residues 1252-1307) that spans the cytosolic domains (Fig. 2a) . A short helical segment of the C-terminal tail (H1 C-tail ; residues 1252-1263) interacts with a unique helical insertion on the P domain, whereas the rest of the tail extends to position a conserved GFAFS motif (residues 1274-1278) at the vertex between the cytosolic domains (Fig. 2a) , and overlaps with the nucleotidebinding site (Fig. 2b) . Autoinhibition is further stabilized by the clamping of a short loop region in the N domain (residues 698-704) over the GFAFS motif. Cleavage of the C terminus at residue 1290 results in a 10-20-fold increase in enzyme activity compared to wild-type Drs2p-Cdc50p
26
, as it removes the bulk of the C-terminal region that interacts with the A domain (as well as unmodelled terminal residues). , coloured by domain: the A, P and N domains of Drs2p are yellow, blue and red, respectively; the transmembrane domain is tan; the autoinhibitory C terminus is green; and Cdc50p is pink. Unmodelled map features that correspond to ordered lipid or detergent molecules are orange. b, Cartoon representation of the refined E2P inhib model. Colours are as in a. C-tail highlighted in light green to emphasize its disassociation after the binding of PI4P. The first and last residues that are modelled around the disordered linker are identified. The lipids occupying the regulatory sites in E2P inter and E2P active are identified: phosphatidylserine (black sticks) and PI4P (purple sticks).
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However, truncation at residue 1302 maintains autoinhibition 26 and preserves the interactions with the A domain. This suggests an allosteric mechanism of autoinhibition, in which the cytosolic domains are locked and prevented from undergoing conformational changes. The 16-residue linker between TM10 and the autoregulatory domain is not resolved sufficiently for modelling, but appears at a low-density threshold and in 2D class averages (Fig. 2c) .
Density is observed for PI4P bound between TM7, TM8 and TM10 of E2P inter and E2P active . Notably, binding of PI4P is concurrent with the movement of the cytosolic ends of TM10 and the transmembrane helices of Cdc50p, and also concurrent with the formation of an amphipathic helix just after TM10. The amphipathic helix propagates away from the autoinhibitory binding site and exerts a pull that dissipates the autoinhibitory interactions of the H1 C-tail with the P domain-thus releasing the P domain. In addition, the amphipathic helix provides a platform for interaction with the TM6-TM7 loop, which moves together with the P domain. This explains in part why C-terminal truncation at residue 1247 preserves PI4P dependence (Extended Data Fig. 1d) , whereas truncation at residue 1232 leads to a flippase that is reportedly independent of PI4P 24 . In E2P inter , only the downstream interactions of the C terminus with the N and A domains remain preserved (Fig. 2d) . The H1
C-tail coincides with the previously described Gea2p-binding site 29 , and its release-mediated by PI4P-exposes it for interaction. The PI4P-binding site, however, is notably distinct from a previously proposed site at basic residues 1268-1273 23 . The position of the PI4P glycerol backbone is stabilized by interactions with several positively charged residues that are located in the transmembrane region of Drs2p, and selectivity for PI4P is provided by the interaction of Tyr1235 and His1236 (displayed by the amphipathic helix) with the inositol-4-phosphate group of PI4P (Fig. 3a, b) . Mutations of these residues strongly attenuate ATPase activity and reduce the susceptibility of the C-terminal tail to limited proteolysis, which indicates that there is a loss of PI4P binding (Fig. 3c , Extended Data Fig. 4, Supplementary Information) . Notably, the PI4P-binding site of Drs2p is located in the same region as the C-terminal YY motif of the α-subunit of the Na (Fig. 3d) . In E2P inhib , the amphipathic helix is not present, and the vacant PI4P site contains a lipid with a markedly smaller head group that shows no specific interactions (Fig. 3e) . We modelled it as phosphatidylserinewhich was the only lipid added to the sample during purification-and presume that regular phospholipids are bound in a non-selective manner in the autoinhibited state.
A putative site for substrate entry
E2P
active and E2P inter are largely similar. However, the lack of an autoinhibitory domain in E2P active allows for further rearrangements of the N and A domains, which causes the transmembrane domain to exhibit a conformation that is more open than E2P inter and E2P inhib . In this arrangement, movements of the transmembrane regions TM1 and-in particular-TM2 expose the unwound segment of TM4 to the luminal leaflet of the membrane (Fig. 4a, b) . This conserved PISL motif has been implicated in lipid transport 14 . The region of TM4 that is exposed to the lumen is lined by TM1, TM2 and TM6, and we propose that this cleft (which is empty in our structures) marks the entry point of a lipid-transport pathway. The cleft partially overlaps with a previously proposed entry gate, and contains residues that are important for lipid specificity 12 . In particular, Gln237, which is part of a conserved QQ motif at the end of TM1, points into the open cleft-supporting the role of Gln237 in substrate specificity (Fig. 4c) . The cleft is also consistent with a previously proposed hydrophobic gate model 7 in which the conserved isoleucine residue (Ile508 in Drs2p) of the PISL motif 14 has a central role-although the conformation of TM1 and TM2 in E2P active (and the other E2P states reported here) differs from that suggested in previous homology models.
Chimeric constructs and mutants of the TM1-TM2 loop in Dnf1p and Drs2p lipid flippases have indicated that this loop may have a role in lipid binding and specificity
12
. A conserved arginine residue in the ectodomain of Cdc50p (Arg151) reaches towards the proposed entry site-a position from which it could help to orient the luminal loop between TM1 and TM2 and guide the binding of lipids (Fig. 4c) . As a comparison, in the Na , and the ouabain-binding site overlaps with the putative lipid-entry pathway in Drs2p-Cdc50p (Fig. 4d, f) . Notably, the putative lipid-entry pathway in Drs2p does not span the entire membrane, thus pointing to an alternating-access mechanism of transport. Extension of the pathway towards the cytosolic side overlaps with a lipid-binding site as well as a binding site for the inhibitor cyclopiazonic acid in the sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase (SERCA) 33 ( Fig. 4e, f) . A proposed exit site such as this one, at the cytoplasmic leaflet, would be expected to emerge in a subsequent E2-E1 transition of the functional cycle, and hints at possible evolutionary links between lipid flippases and ion pumps.
Unlike in the cation-transporting P2-ATPases (Extended Data Fig. 5b, c) , negatively charged side chains are absent in the transmembrane core of Drs2p, but the potentially positively charged Lys1018 of TM5 interacts with Asn1050 at a bulge of TM6 and could have a stabilizing, yet dynamic, role (Fig. 4g ). Lys1018 has previously been implicated in transport in the bovine flippase ATP8A2
7
, and it projects a potential positive charge at the middle of the transmembrane pathway (Fig. 4a, b, g ). The estimated pK a value 34 of Lys1018 is around 6.8 for E2P inhib and 7.4 for E2P active , which indicates that it may switch between a neutral and a positively charged state as part of dynamic interactions with a negatively charged lipid head group.
Transport mechanism
The movements of the P and N domains in the transition from the constrained E2P inhib state to the E2P inter and E2P active states (Extended Data Fig. 5d ) are mirrored in a concomitant movement of the adjacent TM6-TM7 loop towards the amphipathic helix that forms after PI4P binding (Extended Data Fig. 5e ). This suggests that binding of PI4P leads to the movement of the P domain. Of note, the position of the dephosphorylation loop of the A domain remains locally constant with respect to the P domain (Extended Data Fig. 1g) . Removal of the C terminus allows for increased mobility of the A domain, which may explain why PI4P alone is not sufficient for full activation of the intact enzyme.
On the basis of our results, we propose the following model for autoregulation and exposure of the lipid-entry site. E2P
inhib has a closed transmembrane domain, with the cytosolic domains locked by the autoinhibitory C terminus (Fig. 5, Supplementary Video 2) . Binding of PI4P to the transmembrane domain induces the formation of an amphipathic helix on the C-terminal side of TM10. This helix has two effects. First, it causes the remainder of the C terminus to partially unfold, thus destabilizing its interaction with the P domain through the displacement of the H1 C-tail (which contains the putative Gea2p-binding site); and second, it forms an interaction site for the TM6-TM7 loop, which then moves concurrently with the P domain. Together, these two movements shift the P and N domains towards the amphipathic helix. A progressive rotation of the A domain leads to a subtle movement of TM2 and (to a lesser extent) TM1, which results in the E2P inter state. Full displacement of the C terminus leads to the E2P active state, in which a further rotation of the N and A domains drives the active state (f; this work). View and colours are as in a. For the Na + , K + -ATPase (d), the β-and γ-subunits are pink, TM4 is yellow, the PEGL motif is orange and ouabain is green. For SERCA (e), colours are as in d, and phosphatidylethanolamine molecules are depicted as green spheres. The ouabain-binding site of the Na + , K + -ATPase overlaps with the cleft in E2P
active -Drs2p-Cdc50p. The bound phosphatidylethanolamine in SERCA suggests a putative lipid-exit site in Drs2p-Cdc50p. g, The side chain of Lys1018, near the PISL motif of TM4. This location is marked with an orange asterisk in a.
Article reSeArcH opening of a putative substrate-binding site through the movement of TM2 away from TM6. We anticipate that subsequent binding of the substrate lipid (phosphatidylserine or phosphatidylethanolamine) will be associated with further conformational changes of the transmembrane domain as dephosphorylation takes place.
Conclusion
The structures of Drs2p-Cdc50p presented here provide insights into the architecture of the P4-ATPase lipid flippases and identify the locations of the Cdc50p subunit and the putative substrate lipid-binding site. The structure of the autoinhibitory domain and the conformational changes associated with the binding of PI4P reveal a mechanism by which P4-ATPases autoregulate, as well as suggesting potential sites at which the activity of lipid flippases could be modulated. Further structures that capture the progressive states of lipid binding, dephosphorylation, lipid translocation and cytoplasmic release may enable the mechanism of the lipid flippase to be determined.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/ s41586-019-1344-7. Schematic of Drs2p-Cdc50p. Domains and regions that are functionally important are coloured: the A, P and N domains of Drs2p are yellow, blue and red, respectively; TM1, TM2 and TM4 are dark yellow, orange and wheat rods, respectively; the TM6-TM7 loop is dark blue; the TM10 amphipathic helix is green; the C terminus is dark green; Cdc50p is pink. Lipids are labelled. The grey surface denotes an auxiliary protein (such as Gea2p) sequestering the C terminus to prevent autoinhibition. Binding of PI4P triggers the formation of the C-terminal amphipathic helix, disrupts the binding of the H1 C-tail to the P domain and results in a rigid-body movement of the cytosolic domains and the TM6-TM7 loop. Full release of the autoinhibitory domain leads to further rearrangements of the N and A domains, movements of TM1 and TM2 and the opening of a putative lipid-entry site.
Article reSeArcH
Methods
Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Biochemical studies of C-terminal Drs2p-Cdc50p mutants. Expression and streptavidin purification of wild-type and mutant forms of Drs2p-Cdc50p for functional studies were carried out as previously described 20 . Specifically, we used for this purpose a C-terminal tobacco etch virus (TEV)-cleavable BAD tag, and DDM was used throughout the purification procedure. Size-exclusion chromatography (SEC) was performed on a Superdex 200 Increase 10/300GL column, with a mobile phase containing 0.5 mg ml −1 DDM and 0.025 mg ml −1 POPS in 50 mM MOPS-Tris buffer at pH 7.0, containing 100 mM KCl, 20% glycerol (w/v) and 5 mM MgCl 2 (SSR). ATP hydrolysis by PI4P-binding mutants was measured at 30 °C using an enzyme-coupled assay, by continuously monitoring the rate of NADH oxidation at 340 nm 39 . The purified Drs2p-Cdc50p complexes were added at about 2 µg ml ) and on quantification of Drs2p by SDS-PAGE stained with Coomassie blue, using known amounts of SEC-purified Drs2p as standards.
For limited proteolysis experiments
26
, wild-type and mutant forms of Drs2p-Cdc50p were purified on streptavidin beads, either in the presence or in the absence of POPS. Proteolysis with 40 U ml −1 thrombin took place for 1 h at 20 °C in the presence of 1 mg ml −1 DDM, and 0.05 mg ml −1 phosphatidylserine and/or 0.025 mg ml −1 PI4P when needed. Proteolysis was quenched by adding 1 mM PMSF. Expression and purification of Drs2p-Cdc50p for structural studies. Protein expression in S. cerevisiae, membrane collection and solubilization were performed as previously described 20,26,40 using a C-terminal thrombin-cleavable BAD-tagged Drs2p construct that produces Drs2p ΔN104 -Cdc50p, in which Drs2p is missing the first 104 residues owing to thrombin cleavage. A second construct with an additional thrombin site after residue 1247 in Drs2p resulted in the N-and C-terminally truncated Drs2p
ΔN104/C1247
-Cdc50p sample. Affinity chromatography on streptavidin resin and detergent exchange. The BAD-tagged protein was batch-bound to free streptavidin sepharose resin (typically 1 ml resin per 60 ml of solubilized material) for 1 h at 4 °C. Detergent exchange into LMNG was performed, by washing with 2 column volumes (CV) SSR with 1 mM dithiothreitol (DTT) and 0.2 mg ml −1 LMNG, followed by washing with 10 CV SSR with 1 mM DTT and 0.1 mg ml −1 LMNG. The resin was resuspended in 1 CV SSR with 1 mM DTT, 0.1 mg ml −1 LMNG and 50 µg ml −1 brain phosphatidylserine (Avanti Polar Lipids). Bovine thrombin (4 units per ml resin; Calbiochem) was added to cleave the protein off the resin during an overnight incubation at 4 °C. The protein was eluted from the resin in 10-20 CV SSR with 1 mM DTT and 0.1 mg ml −1 LMNG, and concentrated to 0.5-1 ml in a 100-kDa centrifugal concentrator (Vivaspin) with the sample typically reaching concentrations of 5-10 mg ml −1 .
Cleavage of double-truncated construct. To produce the double-truncated Drs2p
ΔN104/C1247 -Cdc50p protein, after elution from the resin and concentration, 4 U bovine thrombin per ml resin used for the purification was added, along with 0.025 mg ml −1 brain PI4P (Avanti Polar Lipids). This was followed by incubation at room temperature for 1 h and quenching of the protease activity with 1 mM PMSF.
SEC. For Drs2p
ΔN104
-Cdc50p, SEC was run on a Superdex 200 Increase 10/300 column on an ÄKTA purifier system at 4 °C in SSR with 0% glycerol, 1 mM DTT and 0.03 mg ml −1 LMNG. The peak fractions typically resulted in a Drs2p-Cdc50p concentration of 0.6 mg ml −1 , which was used directly for preparation of cryo-EM grids, or stored at −80 °C for later use. For Drs2p
ΔN104/ΔC1247
-Cdc50p, a first round of SEC was run on a TSKg4000SW silica column on an ÄKTA purifier system at 4 °C in SSR with 0% glycerol, 1 mM DTT and 0.03 mg ml −1 LMNG. The peak fractions were pooled and concentrated to 8 mg ml −1 using a centrifugal concentrator with a cut-off of 50 kDa, and stored at −80 °C for later use. A second round of SEC was run on an analytical Superdex 200 Increase 3.2/300 column on an ÄKTA purifier system at 4 °C in SSR with 0% glycerol, 1 mM DTT and 0.03 mg ml −1 LMNG, in which a 50-µl sample was injected, to remove the background detergent produced by concentrating the sample. Pooling of the peak fractions resulted in a protein concentration of 0.6 mg ml −1 , which was used directly for preparation of cryo-EM grids. Representative chromatograms and gels are shown in Extended Data Fig. 2a-c . Activity measurement on purified protein for structural studies. The activity of the purified Drs2p-Cdc50p used for structural studies was assayed using an arsenic-based Baginski assay 41 , which is a colorimetric assay for free inorganic phosphate. Drs2p-Cdc50p in LMNG to a final concentration of 10 µg ml −1 was added to a reaction buffer of SSR with 0% glycerol, 1 mM DTT, 0.02 mg ml −1 LMNG and 5 mM NaN 3 (final concentrations). Phosphatidylserine (with 8-carbon acyl chains (C8:0)), brain PI4P and BeF 3 − (BeSO 4 and KF in a 1:20 molar ratio) were added, when present, to final concentrations of 78 µg ml −1 , 20 µg ml −1 and 1 mM, respectively. After addition of protein to the reaction buffers, the samples were incubated on ice for 1 h, before transfer to 30 °C, and after reaching this temperature, the reactions were initiated by addition of ATP to a concentration of 4 mM. At specific time points, 50 µl of the sample was transferred to a 96-well microplate, and mixed with 50 µl 1:5 solution of 30 mM ammonium heptamolybdate in H 2 O, and 0.17 M ascorbic acid and 0.1% SDS in 0.5 M HCl. After 10 min at room temperature, 75 µl arsenic solution (2% (w/v) anhydrous sodium metaarsenic, 2% (w/v) trisodium citrate dehydrate and 2% (v/v) glacial acid) was added to prevent further complexing of molybdate by phosphate. The plate was left at room temperature for 30 min, before measurement of the absorbance at 860 nm on a Wallac Victor 3 Multilabel Plate Reader (Perkin Elmer). Negative-stain electron microscopy. Copper G400-C3 grids were coated with 2% celluidine, followed by evaporation of amorphous carbon using a Leica EM SCD500 high vacuum sputter coater. Before use, the grids were glow-discharged on a PELCO easiGlow Glow Discharge Cleaning System at 25 mA for 45 s. A total of 3 µl protein sample diluted to 20 µg ml −1 in detergent-free buffer was added, followed by staining 3 times with 3 µl 2% uranyl formate solution, which had been stored at −80 °C. Micrographs were collected on a Tecnai G2 Spirit (120 kV) with a Tietz F416 CCD camera using Leginon 42 . Imaging was performed at 67,000× magnification with a binned camera (pixel size 3.15 Å). Data processing including contrast transfer function (CTF) estimation, particle picking, extraction using a box size of 84 pixels and 2D classification was performed in cisTEM 43 (Extended Data Fig. 2d-f ). Grid preparation for cryo-EM. C-flat Holey Carbon grids, CF-1.2/1.3-4C (Protochips), were glow-discharged on a PELCO easiGlow Glow Discharge Cleaning System at 15 mA for 45 s before addition of 3 µl of 0.6 mg ml −1 Drs2p-Cdc50p in LMNG, which had been incubated on ice for at least 1 h with 1 mM BeSO 4 , 20 mM KF, and 0.1 mg ml −1 brain PI4P when indicated. The samples were vitrified on a Vitrobot IV (Thermo Fisher) at 4 °C and 100% humidity. Cryo-EM data collection. The data were acquired on a Titan Krios with an X-FEG operated at 300 kV. Movies were acquired using a Gatan K2 camera with a Bioquantum energy filter operated at a slit width of 20 eV. Movies were collected in counting mode with a calibrated pixel size of 1.077 Å per pixel at a magnification of 130,000× (Max Planck Institute for Biophysics). Exposures of 8 s fractionated into 40 frames were collected through EPU software (Thermo Fisher) at a dose rate of 1.4 or 1.5 e − per Å 2 per frame, corresponding to a total dose of 56 or 60 e − per Å 2 .
For Drs2p
ΔN104
-Cdc50p, 765 movies were collected on samples with 0.1 mg ml −1 PI4P and 3,069 movies were collected without PI4P. For Drs2p ΔN104/C1247 -Cdc50p, 2,391 movies were collected on a grid with 0.1 mg ml −1 PI4P and 801 movies were collected on a grid without additional PI4P. However, after initial processing the datasets resulted in identical reconstructions with the same density in the PI4P-binding site (probably because of the PI4P that was added during the purification of this sample), and they were treated as one dataset going forward. Cryo-EM data processing. For all three datasets, movie alignment with dose weighting using all frames and CTF determination was performed in cisTEM through Unblur 44 and CTFFIND4 45 , respectively. After manual inspection of the micrographs, 2,050 were selected for Drs2p -Cdc50p with PI4P. The particles were extracted in cisTEM using a box size of 256 pixels, and cisTEM was used for 2D classification (although this was not used for selecting good particles).
For Drs2p
-Cdc50p (E2P inhib ), three ab initio 3D references were generated in cryoSPARC 46 from all particles, which resulted in one class that corresponded to the protein particle and two that corresponded to junk. Three rounds of heterogeneous 3D classification in cryoSPARC were performed in which the first round had one protein class and four junk classes, whereas the next rounds only used two junk classes and one protein class. This resulted in 769,469 particles, which were subjected to heterogeneous 3D refinement, resulting in an initial reconstruction at 3.2 Å from 752,881 particles. These particles were re-extracted in RELION-3 47 from movies that were aligned through MotionCor2 48 (implemented in RELION). Per-particle CTF refinement, with estimation of the beam tilt and Bayesian polishing, was performed in RELION-3 49 , before the final 3D refinement that resulted in an unmasked resolution of 3.0 Å and a masked resolution of 2.8 Å. RELION-3 was used for estimation of the local resolution. The processing strategy is summarized in Extended Data Fig. 6 .
-Cdc50p with PI4P (E2P inter ), three ab initio 3D references were generated in cryoSPARC 46 , resulting in one protein-like class and two junk classes. These were used as reference in 3 rounds of heterogeneous 3D classification that resulted in 291,944 protein particles. An initial homogeneous 3D refinement of these particles resulted in a reconstruction at 3.8 Å from 277,569 particles. These particles were re-extracted in RELION-3
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MotionCor2 48 (implemented in RELION). Per-particle CTF refinement, with estimation of the beam tilt and Bayesian polishing, was performed in RELION-3 49 , before the final 3D refinement that resulted in an unmasked resolution of 3.4 Å. However, this appeared to be a mixed state near TM10 of Drs2p, the PI4P-binding site and in parts of the autoinhibitory domain. As simple 3D classification using the refined map as a reference did not separate this heterogeneity, five new ab initio references were generated in cryoSPARC 46 with similarity 1.0, to allow for classes that were very similar. These were then all used as references for heterogeneous 3D refinement, resulting in one class that corresponded to a PI4P-bound structure, two classes identical to the determined autoinhibited structure in the absence of PI4P and two minor junk classes. The PI4P-bound class resulted in a reconstruction at 3.7 Å from 78,981 particles from cryoSPARC; this reconstruction was also refined in RELION-3 to an unmasked resolution of 3.9 Å and a masked resolution of 3.7 Å after processing. RELION-3 was used for estimation of the local resolution. The processing strategy is summarized in Extended Data Fig. 7 .
ΔN104/C1247
-Cdc50p with PI4P (E2 active ), three ab initio 3D references were generated in cryoSPARC 46 from all particles, resulting in one protein-like class and two junk classes. All particles were then subjected to heterogeneous 3D classification in cryoSPARC, using each junk reference twice and the protein-like class once, which resulted in four junk classes and one class with particles that corresponded to the protein. This class was then subjected to heterogeneous 3D refinement in cryoSPARC, resulting in an initial reconstruction at 3.4 Å from 493,753 particles. The 3D refinement was repeated in RELION-2.1 50 using a soft solvent mask, which resulted in a reconstruction of similar quality. To improve the map, particle sorting was performed in RELION-2.1; particles with a z-score above 0.9 or a defocus higher than 2.0 µm were rejected, and the remaining 418,512 were re-extracted in RELION-3 47 from movies that were aligned through MotionCor2 48 (implemented in RELION). Per-particle CTF refinement, with estimation of the beam tilt and Bayesian polishing, was performed in RELION-3 49 , before the final 3D refinement that resulted in an unmasked resolution of 3.1 Å and a masked resolution of 2.9 Å. RELION-3 was used for estimation of the local resolution. The processing strategy is summarized in Extended Data Fig. 8 .
Data collection and processing statistics are summarized in Extended Data Table 1 .
Model building and refinement. The Drs2p ΔN104/C1247 -Cdc50p with PI4P was built manually in Coot 51 , guided by secondary structure predictions from RaptorX 52 and-for Drs2p-by the structures of the Na + , K + -ATPase and SERCA in the E2P state (PDB 4HYT and 3B9B, respectively), owing to the shared topology and similarity of the E2P conformations in these proteins and Drs2p. For Cdc50p, the positions of all glycosylation sites were visible as at least one sugar moiety, and these were used to validate the de novo traced structure along with the presence of the two disulfide bonds. The model was refined using Namdinator 53 and phenix. real_space_refine 54 . Drs2p ΔN104 -Cdc50p was built by fitting the Drs2p
-Cdc50p model using Namdinator 53 , followed by manual editing in Coot and manual tracing of the autoregulatory C terminus. Coordinate refinement was carried out using phenix. real_space_refine 54 . The Drs2p
ΔN104
-Cdc50p with PI4P model was built based on the other two structures, with manual editing in Coot 51 , followed by phenix. real_space_refine 54 . For Drs2p, the 78 N-terminal residues of the construct, as well as the 46 C-terminal residues and the linker region of 16 residues (20 residues in the structure of E2P inter ) between TM10 and the autoregulatory domain in Drs2p
, were too disordered for modelling or were entirely missing from the density. For Cdc50p, the 19 N-terminal residues (18 in the structure of E2P active ) and the entire C-terminal tail of 33 residues (35 in the structure of E2P inhib ) could not be modelled. Model validation was performed using MolProbity 55 in PHENIX 56 . Modelling and refinement statistics are summarized in Extended Data Table 1 . Model-to-map Fourier shell correlation (FSC) curves and representative densities from different areas of the maps are shown in Extended Data Fig. 9 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Cdc50p E2P inhib . a, Representative motion-corrected and dose-weighted micrograph (defocus 1.6 µm) of autoinhibited Drs2p ΔN104 -Cdc50p in LMNG, frozen at a concentration of 0.6 mg ml −1 . b, Fourier power spectrum of the micrograph shown in a, as well as the fit from CTFFIND 4.1 through cisTEM, which extends to 3 Å. c, Colour code for the processing software. d, Data-processing workflow, indicating the number of particles that remained after each step at which particles were discarded. The densities resulting from 3D refinement are shown in grey, and relevant masks are light blue. The resolutions listed for 3D refinements are at FSC = 0.143. 
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Cryo-EM data was analyzed through the cisTEM 1.0.0-beta package (including Unblur and CTFFIND 4.1 procedures), Relion 2.1 and 3.0 and cryoSPARC v1. Modelling was performed using COOT 0.8.9.1, secondary structure prediction from RaptorX and Namdinator. Phenix 1.14-3260 was used for refinement, Molprobidity, EMRinger and Mtriage were used for validation. LocScale was used for scaling of maps for visualization. All of the software is published and referenced in the supplementary. All but cryoSPARC are open source. No custom algorithms were used.
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